1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2020. Available from: https://gco.iarc.fr/today. Accessed 02 June 2021.
2. Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, Stattin P, Van Poppel H, La Vecchia C. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;S2588–9311(21):00181–4.
3. Carvalho ÍT, Baccaglini W, Claros OR, Chen FK, Kayano PP, Lemos GC, et al. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. Acta Oncol (Madr). 2018;57(8):1003–10.
4. Greco C, Pimentel N, Pares O, Louro V, Fuks ZY. Single-dose radiotherapy (SDRT) in the management of intermediate risk prostate cancer: early results from a phase II randomized trial. J Clin Oncol. 2018;36(6 suppl):128. https://doi.org/10.1200/JCO.2018.36.6_suppl.128.
5. Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events (CTCAE).v.5.0 [5x7]. Cancer Ther Eval Progr [Internet]. 2017;155. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50